Long-term use of SGLT2 inhibitors has been linked to various positive cardiovascular outcomes, including decreased rates of ...

Saman Gunatilake Emeritus Professor of Medicine and Neurologist University of Sri Jayewardenepura Key facts * Substandard and ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Dad of four, Mark Sommerville, who has motor neurone disease (MND) has backed a campaign to fund the clinical trial of a drug ...

Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in subjects with GA ...

Nevrargenics who are behind a drug which they believe not only stops the impact of MND but reverses the damage already done.

As the new year begins, individuals looking to improve their health might consider participating in clinical trials, ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community ...